Read by QxMD icon Read


Dusanka Skundric
This overview is aimed at reevaluating fundamental approaches of current MS therapies with focus being placed on their targeted underlying immune, molecular and cellular mechanisms. Currently used therapies are discussed in regard to their mechanisms of action, clinical accomplishments and unwanted side effects and complications. Special emphasis is given to current disease modifying therapies (DMT) and their actions at immune mechanisms of disease. Effects on DMT on CD4+Th1 cells and related cytokine and signaling pathways are discussed in more detail...
October 18, 2016: Central Nervous System Agents in Medicinal Chemistry
Laorrat Phuapittayalert, Phisid Saenganantakarn, Wisa Supanpaiboon, Supaporn Cheunchoojit, Wiphawi Hipkaeo, Natthiya Sakulsak
Cadmium (Cd) has known to produce many adverse effects on organs including placenta. Many essential transporters are involved in Cd transport pathways such as DMT-1, ZIP as well as L-VDCC. Fourteen pregnant women participated and were divided into two groups: high and low Cd-exposed (H-Cd, L-Cd) groups on the basis of their residential areas, Cd concentrations in the blood (B-Cd), urine (U-Cd), and placenta (P-Cd). The results showed that the B-Cd and U-Cd were significantly increased in H-Cd group (p < 0...
October 15, 2016: Environmental Science and Pollution Research International
Luis Hernandez, Shien Guo, Hector Toro-Diaz, Stuart Carroll, Syed Feisal Syed Farooq
AIMS: Peginterferon beta-1a 125 mcg administered subcutaneously every two weeks, a new disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), was approved in January 2015 by the Scottish Medicines Consortium. This study assesses long-term clinical and economic outcomes of peginterferon beta-1a compared with other self-injectable DMTs (interferon beta-1a [22 mcg, 30 mcg, and 44 mcg], interferon beta-1b, and glatiramer acetate 20 mg) in the treatment of RRMS, from the National Health Service and personal social services perspective in Scotland...
October 12, 2016: Journal of Medical Economics
José Manuel Garcia-Dominguez, Delicias Muñoz, Marta Comellas, Irmina Gonzalbo, Luis Lizán, Carlos Polanco Sánchez
OBJECTIVES: To assess disease-modifying therapy (DMT) preferences in a population of patients with multiple sclerosis (MS) and to estimate the association between sociodemographic and clinical factors and these preferences. METHODS: Preferences for DMTs attributes were measured using a discrete choice experiment. Analysis of preferences was assessed using mixed-logit hierarchical Bayes regression. A multilinear regression was used to evaluate the association between the preferences for each attribute and patients' demographic and clinical characteristics...
2016: Patient Preference and Adherence
Stephen M Hadlow, Ross A Pinder, Mark G L Sayers
In Australian rules football structured increases in ball size during development end with the transition to the Size 5 (adult) ball at the Under-15 age group. This study assessed changes in kick technique and performance in experienced junior performers when using Size 4 and 5 Australian rules footballs. Participants (n = 22, 13.77 ± 0.61 years) performed drop punt kicks in 2 representative tasks; a Decision-Making Test (DMT) (n = 14) and Set-Shot Test (SST) (n = 14 + 8). Results indicate participants sustained their level of kick performance (accuracy and quality of ball spin) in both tests when using a Size 5 football...
October 6, 2016: Journal of Sports Sciences
Xi-Ling Jiang, Hong-Wu Shen, Donald E Mager, Stephan Schmidt, Ai-Ming Yu
We have shown recently that concurrent harmaline, a monoamine oxidase-A inhibitor (MAOI), potentiates serotonin (5-HT) receptor agonist 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)-induced hyperthermia. The objective of this study was to develop an integrated pharmacokinetic/pharmacodynamic (PK/PD) model to characterize and predict the thermoregulatory effects of such serotonergic drugs in mice. Physiological thermoregulation was described by a mechanism-based indirect-response model with adaptive feedback control...
September 2016: Acta Pharmaceutica Sinica. B
Konstantinos Alexandros G Katsogiannis, Goran T Vladisavljevic, Stella Georgiadou, Ramin Rahmani
The effect of pore induction on increasing electrospun fibrous network specific surface area was investigated in this study. Theoretical models based on the available surface area of the fibrous network and exclusion of the surface area lost due to fibre-to-fibre contacts, were developed. The models for calculation of the excluded area are based on Hertzian, Derjaguin-Muller-Toporov (DMT) and Johnson-Kendall-Roberts (JKR) contact models. Overall, the theoretical models correlated the network specific surface area to the material properties including density, surface tension, Young's modulus, Poisson's ratio as well as network physical properties such as density and geometrical characteristics including fibre radius, fibre aspect ratio and network thickness...
October 4, 2016: ACS Applied Materials & Interfaces
Sue-Jie Koo, Imran Chowdhury, Bartosz Szczesny, Xianxiu Wan, Nisha J Garg
BACKGROUND: Trypanosoma cruzi is the causative agent of chronic chagasic cardiomyopathy. Why macrophages (mϕs), the early responders to infection, fail to achieve parasite clearance is not known. METHODS: Mouse (RAW 264.7) and human (THP-1 and primary) mϕs were infected with T. cruzi TcI isolates, SylvioX10/4 (SYL, virulent) and TCC (non-pathogenic), for 3 h and 18 h that represent mϕ stimulation and infection states, respectively. Mϕs incubated with LPS/IFN-γ and IL-4 were used as controls...
October 3, 2016: Infection and Immunity
Attila Szabo, Attila Kovacs, Jordi Riba, Srdjan Djurovic, Eva Rajnavolgyi, Ede Frecska
N,N-dimethyltryptamine (DMT) is a potent endogenous hallucinogen present in the brain of humans and other mammals. Despite extensive research, its physiological role remains largely unknown. Recently, DMT has been found to activate the sigma-1 receptor (Sig-1R), an intracellular chaperone fulfilling an interface role between the endoplasmic reticulum (ER) and mitochondria. It ensures the correct transmission of ER stress into the nucleus resulting in the enhanced production of antistress and antioxidant proteins...
2016: Frontiers in Neuroscience
Shawn David O'Connor, Omar Hoseá Cabrera, Joseph D Dougherty, Sukrit Singh, Brant Stephen Swiney, Patricia Salinas-Contreras, Nuri Bradford Farber, Kevin Kiyoshi Noguchi
OBJECTIVES: Glucocorticoids (GC) are used to improve respiratory mechanics in preterm infants despite clinical evidence linking neonatal GC therapy to cerebellar pathology. In developing mouse cerebellum, the GC dexamethasone (DEX) causes rapid GC-induced neural progenitor cell apoptosis (GINA). Focusing on pharmacological neuroprotection strategies, we investigated whether dexmedetomidine (DMT) protects against GINA. METHODS: Neonatal mice were pretreated with DMT prior to DEX challenge...
September 27, 2016: Journal of Maternal-fetal & Neonatal Medicine
Grazyna Weltrowska, Thi M-D Nguyen, Nga N Chung, JodiAnne Wood, Xiaoyu Ma, Jason Guo, Brian C Wilkes, Yang Ge, André Laferrière, Terence J Coderre, Peter W Schiller
Head-to-tail cyclization of the μ opioid receptor (MOR) agonist [Dmt(1)]DALDA (H-Dmt-d-Arg-Phe-Lys-NH2 (9; Dmt = 2',6'-dimethyltyrosine) resulted in a highly active, selective MOR antagonist, c[-d-Arg-Phe-Lys-Dmt-] (1) ("cyclodal"), with subnanomolar binding affinity. A docking study of cyclodal using the crystal structure of MOR in the inactive form showed a unique binding mode with the two basic residues of the ligand forming salt bridges with the Asp(127) and Glu(229) receptor residues. Cyclodal showed high plasma stability and was able to cross the blood-brain barrier to reverse morphine-induced, centrally mediated analgesia when given intravenously...
October 3, 2016: Journal of Medicinal Chemistry
Valery Risson, Bhaskar Ghodge, Ian C Bonzani, Jonathan R Korn, Jennie Medin, Tanmay Saraykar, Souvik Sengupta, Deepanshu Saini, Melvin Olson
BACKGROUND: An enormous amount of information relevant to public health is being generated directly by online communities. OBJECTIVE: To explore the feasibility of creating a dataset that links patient-reported outcomes data, from a Web-based survey of US patients with multiple sclerosis (MS) recruited on open Internet platforms, to health care utilization information from health care claims databases. The dataset was generated by linkage analysis to a broader MS population in the United States using both pharmacy and medical claims data sources...
2016: Journal of Medical Internet Research
Stanley Cohan, Chiayi Chen, Elizabeth Baraban, Tamela Stuchiner, Lois Grote
BACKGROUND: Since the application of MRI scanning to the diagnosis and treatment of multiple sclerosis, it has been recognized that only a small fraction of lesions seen on MRI scans produce recognizable symptoms or neurological findings. Because new lesions may occur without clinical detection, the recommendation has been made that MRI scanning be performed on a routine scheduled basis, usually yearly, even in patients who are clinically stable. METHODS: A retrospective chart review study was conducted on MS patients who had MRI scans of the central nervous system between 2009 and 2012 at Providence Multiple Sclerosis Center...
2016: BMC Neurology
Gina F Marrone, Zhigang Lu, Grace Rossi, Ankita Narayan, Amanda Hunkele, Sarah Marx, Jin Xu, John Pintar, Susruta Majumdar, Ying-Xian Pan, Gavril W Pasternak
The mu opioid receptor gene undergoes extensive alternative splicing. Mu opioids can be divided into three classes based on the role of different groups of splice variants. Morphine and methadone require only full length seven transmembrane (7TM) variants for analgesia, whereas IBNtxA (3'-iodobenzyol-6β-naltrexamide) needs only truncated 6TM variants. A set of endomorphin analogs fall into a third group that requires both 6TM and 7TM splice variants. Unlike morphine, endomorphin 1 and 2, DAPP (Dmt,d-Ala-Phe-Phe-NH2), and IDAPP (3'-iodo-Dmt-d-Ala-Phe-Phe-NH2) analgesia was lost in an exon 11 knockout mouse lacking 6TM variants...
October 10, 2016: ACS Chemical Neuroscience
Jeffrey Cummings, Paul S Aisen, Bruno DuBois, Lutz Frölich, Clifford R Jack, Roy W Jones, John C Morris, Joel Raskin, Sherie A Dowsett, Philip Scheltens
The global impact of Alzheimer's disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. National leaders have set a goal to prevent or effectively treat AD by 2025. In this paper, we discuss the path to 2025, and what is feasible in this time frame given the realities and challenges of AD drug development, with a focus on disease-modifying therapies (DMTs). Under the current conditions, only drugs currently in late Phase 1 or later will have a chance of being approved by 2025...
2016: Alzheimer's Research & Therapy
Devon S Conway, Nicolas R Thompson, Jeffrey A Cohen
BACKGROUND: The appropriate treatment target in multiple sclerosis (MS) is unclear. Lack of magnetic resonance imaging (MRI) lesion activity, a component of the no evidence of disease activity concept, has been proposed as a treatment target in MS. We used our MS database to investigate whether aggressively pursuing MRI stability by changing disease modifying therapy (DMT) when MRI activity is observed leads to better clinical and imaging outcomes. METHODS: The Knowledge Program (KP) is a database linked to our electronic medical record allowing capture of patient and clinician reported outcomes...
September 2016: Multiple Sclerosis and related Disorders
Vijayshree Yadav, Gail Marracci, Edward Kim, Rebecca Spain, Michelle Cameron, Shannon Overs, Andrew Riddehough, David K B Li, John McDougall, Jesus Lovera, Charles Murchison, Dennis Bourdette
BACKGROUND: The role that dietary interventions can play in multiple sclerosis (MS) management is of huge interest amongst patients and researchers but data evaluating this is limited. Possible effects of a very-low-fat, plant-based dietary intervention on MS related progression and disease activity as measured by brain imaging and MS related symptoms have not been evaluated in a randomized-controlled trial. Despite use of disease modifying therapies (DMT), poor quality of life (QOL) in MS patients can be a significant problem with fatigue being one of the common disabling symptoms...
September 2016: Multiple Sclerosis and related Disorders
Gavin Giovannoni, Helmut Butzkueven, Suhayl Dhib-Jalbut, Jeremy Hobart, Gisela Kobelt, George Pepper, Maria Pia Sormani, Christoph Thalheim, Anthony Traboulsee, Timothy Vollmer
INTRODUCTION: We present international consensus recommendations for improving diagnosis, management and treatment access in multiple sclerosis (MS). Our vision is that these will be used widely among those committed to creating a better future for people with MS and their families. METHODS: Structured discussions and literature searches conducted in 2015 examined the personal and economic impact of MS, current practice in diagnosis, treatment and management, definitions of disease activity and barriers to accessing disease-modifying therapies (DMTs)...
September 2016: Multiple Sclerosis and related Disorders
Xueran Mei, Xiaoyu Zhang, Zhanguo Wang, Ziyang Gao, Gang Liu, Huiling Hu, Liang Zou, Xueli Li
Phlorizin exists in a number of fruits and foods and exhibits many bioactivities. The mechanism of its antidiabetic effect has been known as it can competitively inhibit sodium-glucose symporters (SGLTs). However, phlorizin has a wide range of two-phase metabolism in systemic circulation and shows poor oral bioavailability. An alternative mechanism may involve gut microbiota in intestine. Sixteen obese mice with type 2 diabetes (db/db) and eight age-matched control mice (db/+) were divided into three groups: diabetic group treated with phlorizin (DMT group), vehicle-treated diabetic group (DM group), and normal control group (CC group)...
October 12, 2016: Journal of Agricultural and Food Chemistry
Eunmi Lee, Ji Eun Park, Mayu Iida, Tomoya Fujie, Toshiyuki Kaji, Gaku Ichihara, Young Cheol Weon, Yangho Kim
We report the clinical and neuroimaging findings of 4 men who worked in the production of inorganic metal tin ingot from organotin scrap who presented with similar episodes of reversible amnesia. T2-weighted-fluid-attenuated inversion recovery magnetic resonance imaging (FLAIR MRI) scans in 3 of the patients showed symmetric hyperintensity in the frontoparietal periventricular white matter and the corpus callosum, and reduced apparent diffusion coefficients (ADCs) based on diffusion weighted imaging (DWI). One patient had symmetric faint hyperintensity in the parietal periventricular white matter only in the FLAIR images...
September 11, 2016: Neurotoxicology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"